Patent SG-11201808478R-A (SG)
Title: Fibrotic treatment
Inventor: CHAI SIEW YEEN
IPC: A61P13/12
Filed: 2016-07-29
Abstract: INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property -, Organization 11111111011110111010101111101011111111111101111111110101101111101111011111 International Bureau ... ...... (10) International Publication Number (43) International Publication Date ..... ...,/ WO 2017/015720 Al 2 February 2017 (02.02.2017) W I PO I P CT (51) International Patent Classification: (72) Inventors: CHAI, Siew Yeen; c/- Wellington Road, A61K 31/4433 (2006.01) A61P 19/04 (2006.01) Clayton, Victoria 3800 (AU). WIDDOP, Robert; c/- Wel- A61K 31/4709 (2006.01) A61P 9/00 (2006.01) lington Road, Clayton, Victoria 3800 (AU). GASPARI, A61K 31/351 (2006.01) A61P 17/02 (2006.01) Tracey; c/- Wellington Road, Clayton, Victoria 3800 A61K 38/08 (2006.01) A61P 1/16 (2006.01) (AU). LEE, Huey Wen; c/- Wellington Road, Clayton, A61P 11/00 (2006.01) A61P 13/12 (2006.01) Victoria 3800 (AU). (21) International Application Number: (74) Agent: FPA PATENT ATTORNEYS PTY LTD; Level PCT/AU2016/050681 46, 101 Collins Street, Melbourne, Victoria 3000 (AU). (22) International Filing Date: (81) Designated States (unless otherwise indicated, for every 29 July 2016 (29.07.2016) kind of national protection available): AE, AG, AL, AM, (25) Filing Language: English AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, (26) Publication Language: English DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, (30) Priority Data: KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, 2015903035 30 July 2015 (30.07.2015) AU MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, (71) Applicant: MONASH UNIVERSITY [AU/AU]; Welling- PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, ton Road, Clayton, Victoria 3800 (AU). SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. [Continued on next page] (54) Title: FIBROTIC TREATMENT Figure 1 SY 0 ic Blood Pressure 200 180 .,, - E 160 a., 140 - MI co 120 100 Week 1-1 © ei AO . WT + Saline -et- MAP KO 4' \"mg 11 IN 4 lRA P KO + Saline ..• WY' + Ang 11 .+ Vali 11 in INT +Ana .I WI + Ang it + HP1419 1-1 0 N Il 0 ei [Continued on next page] O WO 2017/015720 Al MIDEDIMOMOIDEIRMEMONIMMEHHOMMOVOIS (84) Designated States (unless otherwise indicated, for every Declarations under Rule 4.17: kind of regional protection available): ARIPO (BW, GH, of inventorship (Rule 4.17(iv)) GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, Published: TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, with international search report (Art. 21(3)) LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). (57) : The present invention relates to a method for the treatment of fibrosis, in particular cardiac fibrosis, comprising the administration of an inhibitor of insulin-regulated aminopeptidase (IRAP). Preferable the IRAP inhibitor is chosen from the group including HFI- 419, HA-08, AL-40, HFI-437, Val-Tyr-Ile-His-Pro-Phe (otherwise known as angiotensin IV or ANG IV), c[Cys- Tyr-Cys]-His-Pro- Phe, and c[Hcy-Tyr-Hcy]-His-Pro-Phe.